Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 18, Number 11—November 2012

CME ACTIVITY

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands

Anna M.M. van Deursen1, Suzan P. van Mens1, Elisabeth A.M. Sanders, Bart J.M. Vlaminckx, Hester E. de Melker, Leo M. Schouls, Sabine C. de Greeff2, Arie van der Ende2Comments to Author , and on behalf of the Invasive Pneumococcal Disease Sentinel Surveillance Laboratory Group
Author affiliations: University Medical Center, Utrecht, the Netherlands (A.M.M. van Deursen, S.P. van Mens, E.A.M. Sanders); Linnaeus Institute, Hoofddorp, the Netherlands (A.M.M. van Deursen); St Antonius Hospital, Nieuwegein, the Netherlands (S.P. van Mens, B.J.M. Vlaminckx); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (H.E. de Melker, L.M. Schouls, S.C. de Greeff); Academic Medical Center, Amsterdam, the Netherlands (A. van der Ende); Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam (A. van der Ende)

Main Article

Table 2

Incidence of invasive pneumococcal disease manifestations before and after implementation of a PCV7 vaccination program, the Netherlands, June 2004–May 2010*

Age group, y, manifestation Incidence (%) by infecting serotype and vaccination period†
All serotypes

PCV7 serotypes

Non–PCV7 serotypes
Pre-implementation Late post-implementation Pre-implementation Late post-implementation Pre-implementation Late post-implementation
<5

Meningitis

6.80 3.88 4.80 0.43 2.00 3.45

Invasive pneumonia

4.40 1.72 3.00 0 1.40 1.72

Bacteremia other focus

3.60 1.29 2.80 0 0.80 1.29

Bacteremia without focus

3.80 1.29 2.40 0.22 1.40 1.08
5–64

Meningitis

1.05 1.07 0.48 0.24 0.57 0.82

Invasive pneumonia

4.92 5.36 1.94 1.18 2.98 4.18

Bacteremia other focus

0.45 0.41 0.15 0.14 0.29 0.27

Bacteremia without focus

0.55 0.47 0.20 0.09 0.35 0.38
>65

Meningitis

3.38 2.24 1.39 0.40 1.99 1.84

Invasive pneumonia

47.80 40.80 23.21 10.14 24.51 30.66

Bacteremia other focus

1.73 2.63 0.78 0.64 0.95 2.00

Bacteremia without focus

4.42 3.99 2.16 1.12 2.25 2.87

*Incidence is per 100,000 inhabitants. PCV7, 7-valent pneumococcal conjugate vaccine.
†Vaccination periods: pre-implementation period, June 2004–May 2006; late post-implementation period, June 2008–May 2010.

Main Article

1These authors contributed equally to this article.

2These authors contributed equally to this article.

3Additional members of the Invasive Pneumococcal Disease Sentinel Surveillance Laboratory Group are listed at the end of this article.

Members of the Invasive Pneumococcal Disease Sentinel Surveillance Laboratory Group: Karola Waar, Izore, Centre for Infectious Diseases Friesland, Leeuwarden, the Netherlands; Bert Mulder, Laboratory of Medical Microbiology Twente Achterhoek, Enschede, the Netherlands; Caroline Swanink, Department of Medical Microbiology and Medical Immunology Hospital Rijnstate, Arnhem, the Netherlands; Bram Diederen, Regional Laboratory of Public Health, Haarlem, the Netherlands; Niek Arents, Laboratory for Pathology and Medical Microbiology, Veldhoven, the Netherlands; Ine Frénay, Regional Laboratory for Medical Microbiology and Infectious Diseases, Dordrecht–Gorinchem, the Netherlands; Hans Wagenvoort, Atrium Medical Center, Heerlen, the Netherlands; Bartelt de Jongh, St. Antonius Hospital, Nieuwegein, the Netherlands; Lodewijk Spanjaard, Academic Medical Center, Amsterdam, the Netherlands

TOP